Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

• Status: Recruiting
• Trial end date: 2024-07-31
• Target enrollment: 0
• Participant gender: All

Summary

This open-labeled, multicenter study is designed to evaluate the efficacy, safety and PK/PD of roxadustat in ESA-naïve and ESA-treated pediatric patients with CKD Stages 3, 4, and 5, as well as end-stage renal disease (ESRD) who are receiving either hemodialysis (HD) or peritoneal dialysis (PD). The study will enroll patients between the ages of 2 to <18 years in two sequential cohorts, with the older cohort of ages 12 to <18 years enrolled first. Approximately 30 patients will be enrolled in each age-based cohort.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: FibroGen
• Collaborator: AstraZeneca

Criteria

Important Inclusion Criteria:

• Clinically stable CKD in the opinion of the investigator.

• Estimated glomerular filtration rate (Bedside Schwartz formula) of < 60 ml/min/1.73 m2 (stage 3, 4 and 5 CKD) for non-dialysis patients, or patients who are receiving chronic dialysis (hemodialysis or peritoneal dialysis) for ESRD.

• For ESA-naïve patients (either NDD or DD; ESA-naïve is defined as those patients whose total duration of prior ESA exposure is ≤ 3 weeks within the preceding 12 weeks at the time informed consent is obtained), mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be < 11.0 g/dL. For patients currently receiving stable ESA dosing who will discontinue ESA and convert to roxadustat during study, mean of two most recent central laboratory Hb values during the screening period obtained at least 2 days apart must be ≥ 10.0 g/dL and ≤ 12.5 g/dL.

• Ferritin >50 ng/mL and transferrin saturation >10% (obtained from screening visit).

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2x upper limit of normal (ULN) and total bilirubin (Tbili) ≤1.5x ULN at randomization (obtained from screening visit).

• Serum folate and vitamin B12 > LLN (obtained from screening visit).

Important Exclusion Criteria:

• Uncontrolled hypertension as judged by the principal investigator in the 2 weeks prior to screening.

• Known hematologic disease other than anemia associated with CKD.

• Known malignancy within the past 5 years before screening.

• Any prior organ transplant or any planned organ transplant during the study period.

• Any RBC transfusion during the past 8 weeks before screening.

• Any condition leading to significant blood loss (e.g., gastrointestinal bleeding, surgical procedures) within 8 weeks before screening or during the screening period.

• History of chronic liver disease.

• Pure red cell aplasia (PRCA) or history of PRCA.

• History of epileptic seizures.

• History of hyperlipidemia or significant thrombotic/thromboembolic event (e.g., deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction).

• History of thrombosis of an arteriovenous fistula/graft within 12 weeks prior to enrollment.

• Any active systemic or significant infection or episode of peritonitis within 30 days of screening.

• Any statin use within 30 days of screening.

• Any prior exposure to roxadustat or any other HIF-PH inhibitor.